Race, Socioeconomic Status, Treatment, and Survival Time among Pancreatic Cancer Cases in California
- 1 March 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 16 (3) , 546-552
- https://doi.org/10.1158/1055-9965.epi-06-0893
Abstract
Background: Poor survival in pancreatic adenocarcinoma is associated with African-American race and also with low socioeconomic status (SES). However, it is not known whether the observed poor survival of African-American pancreatic adenocarcinoma cases is due to SES itself and/or treatment disparities. We set out to determine this using the large, population-based California Cancer Registry (CCR) database as a model.Keywords
This publication has 19 references indexed in Scilit:
- Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populationsCancer, 2006
- Colorectal cancer stage at diagnosis by socioeconomic and urban/rural status in California, 1988–2000Cancer, 2006
- Prognostic factors for survival in pancreatic cancer: a population-based studyThe American Journal of Surgery, 2006
- Survival Among Patients with Adenocarcinoma of the Pancreas: A Population-based Study (United States)Cancer Causes & Control, 2006
- Epidemiology of Bronchioloalveolar Carcinoma: Improvement in Survival After Release of the 1999 WHO Classification of Lung TumorsJournal of Clinical Oncology, 2005
- Differences in Survival by Histologic Type of Pancreatic CancerCancer Epidemiology, Biomarkers & Prevention, 2005
- Patterns of Chemotherapy Use for Women With Ovarian Cancer: A Population-Based StudyJournal of Clinical Oncology, 2003
- Influence of specialization on the management and outcome of patients with pancreatic cancerBritish Journal of Surgery, 2003
- Prognostic Factors Following Curative Resection for Pancreatic AdenocarcinomaAnnals of Surgery, 2003
- Predictive Value of Clinical Features at Initial Presentation in Pancreatic Adenocarcinoma : A Series of 308 CasesMedical Oncology, 2002